Just Accepted by Journal of Medical Economics
Cost-effectiveness analysis of febuxostat in patients with gout in Spain F. Perez-Ruiz, C. Díaz-Torné, D. Carcedo Doi: 10.3111/13696998.2016.1149482 Abstract OBJECTIVES: Cost-effectiveness of febuxostat compared with allopurinol in the treatment of hyperuricemia in patients with gout. METHODS: Costs, clinical outcomes, and QALYs were estimated using a Markov model. Febuxostat 80mg and 120mg sequentially, used as first line and second line therapy, was compared with allopurinol 300mg. Patients switched to the next treat‐ ment in the sequence according to a dichotomous response versus no response (target serum urate level
Cost-effectiveness analysis of febuxostat in patients with gout in Spain F. Perez-Ruiz, C. Díaz-Torné, D. Carcedo Doi: 10.3111/13696998.2016.1149482 Abstract OBJECTIVES: Cost-effectiveness of febuxostat compared with allopurinol in the treatment of hyperuricemia in patients with gout. METHODS: Costs, clinical outcomes, and QALYs were estimated using a Markov model. Febuxostat 80mg and 120mg sequentially, used as first line and second line therapy, was compared with allopurinol 300mg. Patients switched to the next treat‐ ment in the sequence according to a dichotomous response versus no response (target serum urate level
